DUPAN-II normalisation as a biological indicator during preoperative chemoradiation therapy for resectable and borderline resectable pancreatic cancer.
Cancer
DUPAN-II
Pancreas
Preoperative chemoradiation therapy
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
18 Jan 2023
18 Jan 2023
Historique:
received:
30
10
2022
accepted:
04
01
2023
entrez:
18
1
2023
pubmed:
19
1
2023
medline:
21
1
2023
Statut:
epublish
Résumé
Duke pancreatic mono-clonal antigen type 2 (DUPAN-II) is a famous tumour maker for pancreatic cancer (PC) as well as carbohydrate antigen 19-9 (CA19-9). We evaluated the clinical implications of DUPAN-II levels as a biological indicator for PC during preoperative chemoradiation therapy (CRT). This retrospective analysis included data from 221 consecutive patients with resectable and borderline resectable PC at diagnosis who underwent preoperative CRT between 2008 and 2017. We focused on 73 patients with elevated pre-CRT DUPAN-II levels (> 230 U/mL; more than 1.5 times the cut-off value for the normal range). Pre- and post-CRT DUPAN-II levels and the changes in DUPAN-II ratio were measured. Univariate analysis identified normalisation of DUPAN-II levels after CRT as a significant prognostic factor (hazard ratio [HR] = 2.06, confidence interval [CI] = 1.03-4.24, p = 0.042). Total normalisation ratio was 49% (n = 36). Overall survival (OS) in patients with normalised DUPAN-II levels was significantly longer than that in 73 patients with elevated levels (5-year survival, 55% vs. 21%, p = 0.032) and in 60 patients who underwent tumour resection (5-year survival, 59% vs. 26%, p = 0.039). Normalisation of DUPAN-II levels during preoperative CRT was a significant prognostic factor and could be an indicator to monitor treatment efficacy and predict patient prognosis.
Sections du résumé
BACKGROUND
BACKGROUND
Duke pancreatic mono-clonal antigen type 2 (DUPAN-II) is a famous tumour maker for pancreatic cancer (PC) as well as carbohydrate antigen 19-9 (CA19-9). We evaluated the clinical implications of DUPAN-II levels as a biological indicator for PC during preoperative chemoradiation therapy (CRT).
METHODS
METHODS
This retrospective analysis included data from 221 consecutive patients with resectable and borderline resectable PC at diagnosis who underwent preoperative CRT between 2008 and 2017. We focused on 73 patients with elevated pre-CRT DUPAN-II levels (> 230 U/mL; more than 1.5 times the cut-off value for the normal range). Pre- and post-CRT DUPAN-II levels and the changes in DUPAN-II ratio were measured.
RESULTS
RESULTS
Univariate analysis identified normalisation of DUPAN-II levels after CRT as a significant prognostic factor (hazard ratio [HR] = 2.06, confidence interval [CI] = 1.03-4.24, p = 0.042). Total normalisation ratio was 49% (n = 36). Overall survival (OS) in patients with normalised DUPAN-II levels was significantly longer than that in 73 patients with elevated levels (5-year survival, 55% vs. 21%, p = 0.032) and in 60 patients who underwent tumour resection (5-year survival, 59% vs. 26%, p = 0.039).
CONCLUSION
CONCLUSIONS
Normalisation of DUPAN-II levels during preoperative CRT was a significant prognostic factor and could be an indicator to monitor treatment efficacy and predict patient prognosis.
Identifiants
pubmed: 36653747
doi: 10.1186/s12885-023-10512-2
pii: 10.1186/s12885-023-10512-2
pmc: PMC9850710
doi:
Substances chimiques
Environmental Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
63Subventions
Organisme : JSPS KAKENHI Grant
ID : JP20K09069
Organisme : JSPS KAKENHI Grant
ID : JP20K09069
Organisme : JSPS KAKENHI Grant
ID : JP20K09069
Informations de copyright
© 2023. The Author(s).
Références
JAMA Surg. 2016 Aug 17;151(8):e161137
pubmed: 27275632
JAMA. 2013 Oct 9;310(14):1473-81
pubmed: 24104372
Ann Surg. 2020 Apr;271(4):740-747
pubmed: 30312198
Ann Surg Oncol. 2019 Jun;26(6):1629-1636
pubmed: 30610555
Pancreatology. 2020 Jul;20(5):919-928
pubmed: 32563596
Am J Surg. 1994 Oct;168(4):361-4
pubmed: 7943597
J Clin Oncol. 2020 Jun 1;38(16):1763-1773
pubmed: 32105518
Cancer Chemother Pharmacol. 2017 Apr;79(4):801-811
pubmed: 28314992
Ann Surg Oncol. 2020 Oct;27(10):3950-3960
pubmed: 32318949
Surgery. 2014 Jun;155(6):977-88
pubmed: 24856119
Pancreatology. 2020 Mar;20(2):247-253
pubmed: 31889624
Ann Surg. 2016 Dec;264(6):1091-1097
pubmed: 27462960
Pancreatology. 2021 Jan;21(1):130-137
pubmed: 33303373
Ann Surg. 2013 Dec;258(6):1040-50
pubmed: 23799421
Ann Surg Oncol. 2020 Jun;27(6):2081-2089
pubmed: 31673938
J Natl Compr Canc Netw. 2017 Aug;15(8):1028-1061
pubmed: 28784865
Hepatogastroenterology. 1997 Nov-Dec;44(18):1541-6
pubmed: 9427019
Pancreas. 1994 Nov;9(6):692-7
pubmed: 7531332
Pancreatology. 2016 May-Jun;16(3):434-40
pubmed: 26852169
Pancreatology. 2018 Jan;18(1):2-11
pubmed: 29191513
Ann Surg. 2010 Mar;251(3):461-9
pubmed: 20134315
World J Surg. 2019 Feb;43(2):634-641
pubmed: 30298281
Science. 1981 Apr 3;212(4490):53-5
pubmed: 6163212
Radiother Oncol. 2015 Jan;114(1):122-7
pubmed: 25614389
Ann Surg. 2018 Aug;268(2):215-222
pubmed: 29462005